Initial basic data of patients with t(8;21) and inv(16) treated with or without HAM
| . | t(8;21) . | inv(16) . | Total t(8;21) . | Total inv(16) . | P (χ2) . | ||||
|---|---|---|---|---|---|---|---|---|---|
| HAM . | No HAM . | P (χ2) . | HAM . | No HAM . | P (χ2) . | ||||
| No. of patients | 78 | 53 | 43 | 46 | 131 | 89 | |||
| Median age, y | 9.7 | 11.6 | .22 | 11.6 | 9.8 | .65 | 10.5 | 10.1 | .06 |
| Q1-Q3 | 6.5-14.0 | 8.8-13.9 | 4.9-13.0 | 2.8-13.8 | 7.6-14.0 | 3.3-13.6 | |||
| Leukocytes, × 109μL, median | 9100 | 11 020 | .36 | 34 900 | 50 300 | .15 | 10 400 | 41 900 | < .001 |
| Q1-Q3 | 5600-17 050 | 5700-22 500 | 21 400-108,000 | 15 000-18 200 | 5600-21 000 | 19 735-93 950 | |||
| Sex, no. (%) | |||||||||
| Male | 44 (56) | 27 (52) | .54 | 20 (47) | 25 (54) | .46 | 71 (54) | 45 (51) | .60 |
| Female | 34 (44) | 26 (48) | 23 (53) | 21 (46) | 60 (46) | 44 (49) | |||
| CNS involvement, no. (%) | 5 (6) | 4 (8) | .80 | 14 (35) | 6 (13) | .016 | 9 (7) | 20 (23) | .001 |
| Extramedullary organ involvement, no. (%) | 19 (24) | 12 (23) | .90 | 11 (26) | 11 (24) | .81 | 31 (23) | 22 (25) | .82 |
| Blasts day 15 > 5%,* no. (%) | 18 (23) | 0 (0) | < .001 | 2 (5) | 0 (0) | .14 | 18 (14) | 2 (2) | .005 |
| Cytogenetic data, no. (%) | 71 (91) | 48 (91) | 1.00 | 43 (100) | 36 (78) | 119 (91) | 79 (89) | ||
| Molecular genetic only, no. (%) | 7 (9) | 5 (9) | 1.00 | 0 (0) | 10 (22) | 12 (9) | 10 (11) | ||
| Risk groups, no. (%) | |||||||||
| SR | 54 (69) | 52 (98) | < .001 | 37 (86) | 44 (96) | .11 | 106 (81) | 81 (91) | .04 |
| HR† | 24 (31) | 1 (2) | 6 (14) | 2 (4) | 25 (19) | 8 (9) | |||
| . | t(8;21) . | inv(16) . | Total t(8;21) . | Total inv(16) . | P (χ2) . | ||||
|---|---|---|---|---|---|---|---|---|---|
| HAM . | No HAM . | P (χ2) . | HAM . | No HAM . | P (χ2) . | ||||
| No. of patients | 78 | 53 | 43 | 46 | 131 | 89 | |||
| Median age, y | 9.7 | 11.6 | .22 | 11.6 | 9.8 | .65 | 10.5 | 10.1 | .06 |
| Q1-Q3 | 6.5-14.0 | 8.8-13.9 | 4.9-13.0 | 2.8-13.8 | 7.6-14.0 | 3.3-13.6 | |||
| Leukocytes, × 109μL, median | 9100 | 11 020 | .36 | 34 900 | 50 300 | .15 | 10 400 | 41 900 | < .001 |
| Q1-Q3 | 5600-17 050 | 5700-22 500 | 21 400-108,000 | 15 000-18 200 | 5600-21 000 | 19 735-93 950 | |||
| Sex, no. (%) | |||||||||
| Male | 44 (56) | 27 (52) | .54 | 20 (47) | 25 (54) | .46 | 71 (54) | 45 (51) | .60 |
| Female | 34 (44) | 26 (48) | 23 (53) | 21 (46) | 60 (46) | 44 (49) | |||
| CNS involvement, no. (%) | 5 (6) | 4 (8) | .80 | 14 (35) | 6 (13) | .016 | 9 (7) | 20 (23) | .001 |
| Extramedullary organ involvement, no. (%) | 19 (24) | 12 (23) | .90 | 11 (26) | 11 (24) | .81 | 31 (23) | 22 (25) | .82 |
| Blasts day 15 > 5%,* no. (%) | 18 (23) | 0 (0) | < .001 | 2 (5) | 0 (0) | .14 | 18 (14) | 2 (2) | .005 |
| Cytogenetic data, no. (%) | 71 (91) | 48 (91) | 1.00 | 43 (100) | 36 (78) | 119 (91) | 79 (89) | ||
| Molecular genetic only, no. (%) | 7 (9) | 5 (9) | 1.00 | 0 (0) | 10 (22) | 12 (9) | 10 (11) | ||
| Risk groups, no. (%) | |||||||||
| SR | 54 (69) | 52 (98) | < .001 | 37 (86) | 44 (96) | .11 | 106 (81) | 81 (91) | .04 |
| HR† | 24 (31) | 1 (2) | 6 (14) | 2 (4) | 25 (19) | 8 (9) | |||